The Firm advised Conscio Group in its acquisition of R&D and manufacturing expert for the pharmaceutical industry. Willkie recently advised Conscio Holding GmbH (Conscio Group) on its acquisition of Gen-Plus GmbH & Co. KG, a technology and innovation expert for the pharmaceutical industry. Headquartered in Munich, Germany, Gen-Plus is an R&D and manufacturing expert for the pharmaceutical industry, from proof-of-concept to clinical trial samples and small batch GMP production. It has extensive experience in the key pharmaceutical technologies of patches and thin films, 2D and 3D printing of drugs, highly potent drugs and narcotics, hot melt extrusion, and tailored release profiles. Conscio Group is an independent network of service providers offering pharmaceutical analysis, bioanalytical testing, analytical R&D, clinical studies, biopharma analyses, QC analyses, batch release, and IMPD compilation. Conscio Group is backed by BBA Capital Partners, an independent owner-financed investment group. The Willkie team was led by partners Dr. Maximilian Schwab and Miriam Steets, and included partner Dr. Bettina Bokeloh and associates Sebastian Brenner, Nils Bock and Nicolas Kersten.